The Kids Research Institute Australia logo
Donate

Discover Prevent Cure

The Platform Trial In COVID-19 priming and BOOsting : The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.

Citation:
McLeod C, Dymock M, Flanagan KL, ....... Wadia U, Tjiam MC, Blyth CC, Subbarao K, ....... Thornton RB, Ellis Z, McKenzie A, Marsh JA, Snelling TL, Richmond PC. The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old. J Infect. 2024;89(6).

Keywords:
Adaptive trial; COVID-19; Immunisation; Policy; Vaccination

Abstract:
PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.